New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 22, 2013
09:04 EDTFLMLJudge dismisses 2007 class action case against Flamel Technologies
Flamel Technologies announced that Judge Robert Sweet of the United States District Court for the Southern District of New York issued a summary judgment on March 8 dismissing a class action suit against the company, and its former CEO. The initial class action was filed in 2007 and, during the six year period, had two different plaintiffs. The case, Billhofer v. Flamel Technologies, et al., alleged claims arising under the Securities Exchange Act of 1934 based on certain public statements by the company concerning, among other things, Coreg CR. The Company previously stated that it intended to vigorously defend itself in the action. In dismissing the case, Judge Sweet's opinion states that "as there is no genuine issue of fact and no reasonable jury could find in the lead plaintiff's favor on his claim, the motion for summary judgment is granted."
News For FLML From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 22, 2015
06:55 EDTFLMLFlamel Technologies management to meet with SunTrust
Subscribe for More Information
06:54 EDTFLMLFlamel Technologies management to meet with JMP Securities
Subscribe for More Information
January 16, 2015
08:58 EDTFLMLFlamel Technologies price increase positive, says SunTrust
Subscribe for More Information
January 15, 2015
12:26 EDTFLMLOn The Fly: Midday Wrap
Subscribe for More Information
11:20 EDTFLMLFlamel Technologies announces price increase for Bloxiverz
Subscribe for More Information
09:17 EDTFLMLFlamel Technologies weakness creates buying opportunity, says SunTrust
Subscribe for More Information
08:47 EDTFLMLFlamel Technologies price target lowered to $17 from $22 at Roth Capital
Roth Capital cut its price target on Flamel (FLML) after the FDA approved Fresenius Kabi's (FMS) New Drug Application for neostigmine methylsulfate, a drug which Flamel currently markets as Bloxiverz. Roth expects eostigmine to become a two player market, but adds that price increases by Flamel could mitigate the negative impacts on Flamel's growth. The firm keeps a Buy rating on Flamel.
08:43 EDTFLMLFlamel Technologies pullback an overreaction, says Summer Street
Subscribe for More Information
07:36 EDTFLMLFlamel Technologies sell-off yesterday overdone, says Leerink
Subscribe for More Information
January 14, 2015
16:33 EDTFLMLOn The Fly: Closing Wrap
Subscribe for More Information
14:10 EDTFLMLFlamel Technologies weakness a buying opportunity, says SunTrust
Subscribe for More Information
13:17 EDTFLMLFlamel says evaluating options after Kabi's NDA approval
Subscribe for More Information
12:49 EDTFLMLOn The Fly: Midday Wrap
Subscribe for More Information
12:09 EDTFLMLFlamel Technologies plunges after Jazz gets favorable patent ruling
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use